Key points are not available for this paper at this time.
This Viewpoint discusses whether commonly occuring, sometimes divergent interpretations of new evidence’s validity and usefulness should be explained when experts and guideline committees provide recommendations for screening or treatment.
Bauchner et al. (Fri,) studied this question.